Eric Halioua

Company: PDC*line Pharma

Seminars:

New Class of Antigen-Specific Cancer Active Immunotherapies Based on an Off-the-Shelf Antigen Presenting Cell Line (PDC*line) 3:30 pm

PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors The technology can be applied for any cancerRead more

day: Day One

Panel Discussion: Examining the Impact of the Pandemic on Global Supply Chain to Gain Insight Into Next Strategy Steps 2:30 pm

Discussing strategy for producing cancer vaccines on an industrial scale under GMP conditions Exploring how companies have handled the low availability of raw materials (DNA vectors/ viral vectors) due to priority of Covid-19 for manufacturers Assessing the best strategy to deal with the logistical manufacturing issues that have arisen due to the pandemic Providing insight…Read more

day: Day Two Track B AM